An oral nanocombinatorial agent exhibits pleiotropic improvement in diabetic nephropathy via modulation of the SCAP/SREBPs pathway - PubMed
5 hours ago
- #Diabetic Nephropathy
- #Nanoparticles
- #SCAP/SREBPs Pathway
- The study identifies the SCAP/SREBPs pathway as a central driver in diabetic nephropathy (DN), promoting lipid metabolic disorders and inflammation.
- A nanoparticle library was screened, leading to the discovery of chitosan-lycorine nanoparticles (CLNPs) as an optimal candidate for treating DN.
- Oral CLNPs effectively alleviated renal injury in a murine DN model by reducing lipid accumulation and inflammation, without causing hepatotoxicity.
- CLNPs offer a safer alternative to free lycorine, enabling prolonged therapy with reduced mortality.
- The findings suggest a generalizable strategy for treating complex diseases using a single combinatorial agent targeting multiple pathological injuries.